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Summary. Background: In the OASIS-5 trial, fondaparinux
reduced major bleeding with similar short-term eﬃcacy as
enoxaparin but lowered death and stroke during long-term
follow-up. The mechanism of lower bleeding and improved
eﬃcacy with fondaparinux is uncertain. Methods and Results:
Wecompared the anti-Xa concentration (reﬂecting drug levels),
Xa clot time (reﬂecting anticoagulant eﬀect) and endogenous
thrombin potential (ETP; a global test of hemostatic function)
in plasma samples collected 6, 24 and 72 h after the ﬁrst dose of
the study drug in 48 patients randomly assigned fondaparinux
2.5 mg day)1 and 42 patients assigned enoxaparin 1 mg kg)1
twice daily in the OASIS-5 trial. Patients assigned to fondapar-
inux compared with enoxaparin had a signiﬁcantly lower mean
anti-Xa level [0.52 IU mL)1 (SD 0.22 IU mL)1) vs. 1.2
IU mL)1 (SD 0.45 IU mL)1), P < 0.0001] and Xa clot
time [64.9 s (SD 17.7 s) vs. 111.8 s (SD 29.6 s), P < 0.0001],
and signiﬁcantly higher ETP area under the curve (AUC)
[386.7 mA (SD 51.5 mA) vs. 206.4 mA (SD 90.6 mA),
P < 0.001] at 6 h, and these diﬀerences remained evident at
24 and 72 h. Therewas signiﬁcantly less variability of the results
of anti-Xa levels, Xa clot time and ETPAUC for fondaparinux
compared with enoxaparin at 6 h (P < 0.001 for each
comparison). Conclusion: Fondaparinux 2.5 mg day)1 com-
pared with enoxaparin 1 mg kg)1 twice daily produces less
variable anticoagulant eﬀect and lower mean anticoagulant
intensity. These results most likely explain the reduced risk of
bleeding seen with fondaparinux compared with enoxaparin in
the OASIS-5 trial and suggest that a lower intensity of
anticoagulation than used in the past may be suﬃcient to
prevent recurrent ischemic events and death in patients
with ACS who are concurrently treated with aspirin and
clopidogrel.
Keywords: anticoagulants, hemorrhage, heparin, myocardial
infarction.
Introduction
Anticoagulants are effective in acute coronary syndromes
(ACS) for the prevention of recurrent ischemic events and
death. The major side effect of anticoagulant therapy is
bleeding. Historically bleeding has been considered a reversible
outcome, while thrombotic sequelae such as myocardial
infarction and stroke are irreversible. Recently, evidence has
accumulated that bleeding in patients with ACS is associated
with an increased risk of later ischemic events and death [1–3],
an observation that emphasizes the general principle of
selecting the lowest effective anticoagulant dosage for each
indication. In the Organization to Assess Strategies in Acute
Ischemic Syndromes (OASIS)-5 trial [4,5], which compared
fondaparinux with enoxaparin in patients with non-ST-eleva-
tion acute coronary syndromes (NSTE-ACS), fondaparinux
resulted in (i) similar rates of early ischemic events, (ii)
signiﬁcantly lower rates of bleeding complications, and (iii)
signiﬁcantly lower rates of long-termmortality, compared with
enoxaparin.
It has been suggested that the results of the OASIS-5 trial are
due to pharmacological differences between fondaparinux and
enoxaparin. Fondaparinux is a selective inhibitor of activated
factor X (FXa) while enoxaparin blocks both FXa and, to a
lesser extent, thrombin (FIIa), and it is theoretically possible
that the additional inhibition of FIIa increases the risk of bleed-
ing without providing additional efﬁcacy. This explanation is,
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however, unlikely given other evidence that inhibition of FIIa
prevents recurrent ischemic events in patients with ACS [6,7]. A
more likely explanation is that reduced bleeding with fonda-
parinux is due to the lower anticoagulant intensity afforded by
fondaparinux 2.5 mg day)1 compared with enoxaparin
1 mg kg)1 twice daily (or a reduced dose of 1 mg kg)1 once
daily in patients with a creatinine clearance £ 30 mL min)1).
Of interest and potential importance, the 2.5 mg day)1 dose of
fondaparinux provided sufﬁcient antithrombotic activity, pos-
sibly because patients were receiving other antithrombotic
medications (aspirin, clopidogrel) and therefore did not need
more intense anticoagulant treatment.
We tested our hypothesis that fondaparinux given at a dose
of 2.5 mg subcutaneously once daily, as used in the OASIS-5
trial, provides less intensive anticoagulation than enoxaparin at
a dose of 1 mg kg)1 twice daily, by comparing the anticoag-
ulant intensities used in the OASIS-5 study. The comparison
was performed by measuring the anti-Xa concentration and
activity of the drugs, and by a global assay of hemostasis that
measures thrombin generation, the endogenous thrombin
potential (ETP) [8–10]. We measured the anti-Xa concentra-
tion, anti-Xa activity and the ETP in plasma samples collected
6, 24 and 72 h after the ﬁrst dose of the study drug in 48
patients randomly assigned fondaparinux and 42 patients
randomly assigned enoxaparin in the OASIS-5 trial.
Methods
OASIS-5 was an international randomized double-blind trial
evaluating the efﬁcacy and safety of fondaparinux vs. enoxap-
arin in the acute treatment of NSTE-ACS. The primary aim of
the study was to determine if fondaparinux is non-inferior to
enoxaparin in the prevention of death, new myocardial
infarction and refractory ischemia at 9 days (primary outcome)
and at 30 days (secondary outcome) after randomization [4,5].
The study was approved by the Institutional Review Board at
each participating centre and all patients provided written
informed consent.
Patients
The design of theOASIS-5 study has been published previously
[5].Brieﬂy, patientswere randomizedas soonaspossible, andno
more than 24 h after presentation with signs and symptoms of
unstable angina or non-ST elevationmyocardial infarction. For
inclusionintothestudy,patientswererequiredtomeettwooutof
thefollowingthreecriteria:age‡ 60 years,troponinTorIorCK-
MB elevated greater than the upper limit of normal, and
electrocardiogram changes compatible with ischemia. Patients
with a contraindication to low-molecular-weight heparin
(LMWH), such as renal insufﬁciency [deﬁned as a serum
creatinine of at least 3 mg dL)1 (265 lmol L)1)] or recent
hemorrhagic stroke, and those with an indication for oral
anticoagulation other than an acute coronary syndrome were
excluded. In patients whose creatinine clearance was below
30 mL min)1, the enoxaparin dosagewas reduced (see below).
Study treatments
If a patient had received anticoagulant therapy prior to entry
into the trial, randomization was delayed by 6 h if LMWHwas
administered, and delayed by 2 h if unfractionated heparin
(UFH) was administered. As soon as possible after random-
ization a ﬁrst dose of enoxaparin/enoxaparin-placebo
(1 mg kg)1 twice daily or 1 mg kg)1 once daily in those with
a creatinine clearance < 30 mL min)1) and a ﬁrst dose of
fondaparinux/fondaparinux-placebo (2.5 mg 0.5 mL)1 once
daily) were administered subcutaneously.
Blood sample collection
Investigators at participating centres were encouraged to
approach all patients participating in the OASSIS-5 study for
consent to collect blood samples at baseline (prior to
receiving the ﬁrst doses of the study drug) and at 6, 24
and 72 h after randomization. Blood was drawn from an
antecubital vein by clean venepuncture using a 21-gauge
needle without a tourniquet into two 5 mL vacutainer tubes
preﬁlled with 0Æ5 mL of 3Æ2% buffered sodium citrate
(Becton Dickinson, Toronto, ON, Canada). The blood
collection tubes were kept on ice for a maximum of
30 min before centrifugation at 1700 · g for 15 min at room
temperature. The resultant platelet-poor plasma was har-
vested and subjected to a second centrifugation at 1700 · g
for 5 min to ensure complete removal of platelets. Platelet-
free plasma was harvested and frozen in aliquots at )40 to
70 C prior to shipment on dry ice or in liquid nitrogen to
the central laboratory at Hamilton, Canada, where they were
stored at minus 70 C or below until analyzed.
Laboratory analyses
The baseline plasma samples in the enoxaparin and fondapar-
inux groups were compared using a standard activated partial
thromboplastin (aPTT) assay. The relative anticoagulant
intensities of fondaparinux and enoxaparin at 6, 24 and 72 h
were assessed by measurement of the anti-Xa effect using two
assays, a chromogenic anti-Xa assay [11] and a quantitative
assay of anti-Xa intensity, the Xa-clot time [12], in addition to
an assay of thrombin generation, the endogenous thrombin
potential (ETP).
We based our primary analysis on the results obtained from
the 6-h samples, which are most likely to reﬂect near peak anti-
Xa effect for both fondaparinux and enoxaparin following ﬁrst
subcutaneous administration, despite their different half-lives
and pharmacokinetic properties.
All investigators and laboratory personnel remained blinded
to the treatment allocations and codes until completion of the
laboratory assays.
aPTT assay Baseline aPTT assays were performed on the
STA compact coagulometer using Dade Behring FSL aPTT
reagent (Dade Behring, Marburg, Germany); 50 lL of citrated
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plasma is incubated with 50 lL aPTT reagent for 3 min at
37 C followed by 50 lL of 0.2 M CaCl2. The time to clot
formation is recorded in seconds.
Anti-Xa assay The instrument used for anti-Xa activity was
the Amax 190+ (Trinity Biotech, Bray Co. Wicklow, Ireland).
The assay used was the Stachrom Heparin (Diagnostica
Stago, Asnie`res, France).
The assay is performed in the presence of excess FXa and
exogenous antithrombin (AT) to compensate for any deﬁciency
of AT in the plasma. The AT-drug complex neutralizes a given
quantity of FXa. A substrate speciﬁc for FXa is added and the
residual FXa cleaves the substrate, resulting in release of
paranitroaniline (pNA). The reaction is read at an optical
density of 405 nm and is inversely proportional to the amount
of fondaparinux or enoxaparin present in the plasma. The
plasma levels of fondaparinux and enoxaparin are determined
by measuring their anti-Xa activities using a common calibra-
tion line established for both drugs. The common calibration
line was established by making serial dilutions of a known
concentration of enoxaparin (100 mg mL)1) equivalent to
10 000 anti-Xa U mL)1. After dilution 1/100 in normal pooled
plasma to give a concentration of 100 U mL)1, further
dilutions (1, 0.75, 0.5, 0.25, 0.12 and 0.05 U mL)1) were
prepared. Similarly, serial dilutions were made of a known
concentration of fondaparinux (lot 68 exp 05/2009),
2.5 mg 0.5 mL)1 diluting to 50 mg L)1, and then to
1 mg L)1 in normal pooled plasma; 1 mg mL)1 fondparinux
is equivalent to 0.85 anti-Xa U mL)1. The CV for this assay is
8.1% (low) and 3.0% (high).
Xa-clot assay The instrument usedfor this assay was the
Amax 200 (Trinity Biotech, Bray Co. Wicklow, Ireland). The
assay used was the Hemostasis Reference laboratory in-house
assay; components are (Xa 0.275 IU mL)1), AT, 0.025 M
CaCl2, normal plasma, 0.85% NaCl.
Based on the modiﬁed Hepaclot assay [12], the assay is
performed with exogenous AT. Puriﬁed AT is added to the test
plasma, forming an AT-drug complex. Following the addition
of excess puriﬁed FXa the clotting time of the recalciﬁed
plasma sample ismeasured. TheCV for this assay is 8.0% (low)
and 4.4% (high).
Endogenous thrombin potential The instrument used for
endogenous thrombin potential was the BCS (Siemens,
Marburg, Germany).
Current coagulation assays such as the prothrombin time
(PT) and the aPTTmeasure the time at which ﬁbrin ﬁrst forms;
however, at this stage only 1–2% of thrombin may have been
formed. Thus, current coagulation tests do not take into
account the kinetics of hemostatic pathways. The ETP assesses
the overall coagulation status and takes into account proco-
agulant and anticoagulant factor activities. The ETP assay
gives the opportunity to measure thrombin generation contin-
uously by using a slow (low Km and Kcat) chromogenic
substrate, with the parameters to calculate a thrombin gener-
ation curve. The ETP corresponds to the area under the
thrombin generation curve (AUC) and represents the activity
of thrombin multiplied by the time for which it remains active
in plasma. ETP is measured by the conversion kinetics of a
synthetic thrombin substrate, which measures the release of a
chromophore into the plasma sample at a wavelength of
405 nm. Thrombin formation is activated by tissue factor
pathway activation by the addition of a dilute PT reagent
(Dade Innovin; Marburg, Germany) (0.6 lg) with calcium
chloride. The substrate conversion kinetics are recorded by the
BCS system. A mathematical algorithm corrects for the
activity of a2-macroglobulin bound to thrombin. The corrected
reaction curve corresponds to free thrombin kinetics, while the
end level of the curve corresponds to the ETP value. The ETP
value can also be derived from the AUC. The necessary
calculations are performed automatically by the BCS system
and the ETP calculations are analyzed using the Dade Behring
CURVes software. The CV for this assay is 1.1% (normal) and
2.8% (abnormal).
Statistical analyses Baseline characteristics and medications
before and following randomization were compared between
the groups using a chi-square test for categorical variables and
a t-test for continuous variables. The baseline characteristics of
patients included in this study were compared with the baseline
characteristics of the remaining patients in the OASIS-5 study.
Baseline creatinine, aPTT and anti-Xa levels and 6-h anti-
Xa, Xa clot time and ETP AUC levels were compared using t-
tests. Variability of 6-h anti-Xa levels, 6-h Xa clot times and 6-h
ETP AUC levels were compared by testing equality of
variances. Correlation between age, creatinine levels and anti-
Xa assays and ETP (AUC) was measured using a Pearson
correlation coefﬁcient.
We compared the effect of prerandomization treatment with
UFH or LMWH on baseline aPTT and anti-Xa levels in the
randomized treatment groups using a t-test. We performed a
sensitivity analysis to explore the consistency of our results in
patients who received prerandomization treatment with UFH
or LMWH compared with those who did not receive either of
these treatments.
A two-sided P value > 0.05 was considered statistically
signiﬁcant for all comparisons.
Results
Patient selection
The ﬁrst 50 patients in each randomized treatment group in
whom serial blood samples were collected were selected for
inclusion in our analysis. Some of these patients did not have
stored samples available at both baseline and 6 h, leaving 48
patients with samples in the fondaparinux arm and 42 patients
with samples in the enoxaparin arm.
Three of the 90 patients had a creatinine clearance
< 30 mL min)1; two were randomized to receive enoxaparin
and one to receive fondaparinux.
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Twenty-six patients receiving enoxaparin and 28 patients
receiving fondaparinux were pretreated prior to randomization
with either UFH or LMWH. Five patients receiving enoxap-
arin and 11 patients receiving fondaparinux underwent percu-
taneous coronary intervention (PCI) within 6 h of
randomization.
Baseline characteristics
Baseline characteristics, including age and creatinine, of the
patients in the fondaparinux and enoxaparin group were
comparable and were similar to baseline characteristics of
patients in the overall study (Table 1). Themean baseline aPTT
in patients randomized to receive fondaparinux was 38.9 s and
in those randomized to receive enoxaparin was 37.8 s. The
mean baseline anti-Xa level in patients randomized to receive
fondaparinux was 0.63 IU mL)1 and in those randomized to
receive enoxaparin was 0.69 IU mL)1.
Concomitant therapies
There were no signiﬁcant differences between the fondaparinux
and enoxaparin groups regarding the anticoagulant and
antiplatelet medications prior to, and following, randomiza-
tion. Prerandomization treatment with UFH or LMWH did
not affect baseline aPTT or anti-Xa levels (data not presented)
(Table 2).
Laboratory results
Anti-Xa levels: Mean anti-Xa levels at 6 h were about 50%
lower in patients assigned to fondaparinux compared with
those assigned to receive enoxaparin [0.52 IU mL)1 (SD
0.22 IU mL)1) vs. 1.2 IU mL)1 (SD 0.45 IU mL)1), P <
0.001]. There was signiﬁcantly less variability of the anti-Xa
inhibitory effect of fondaparinux compared with enoxaparin
(Table 3, Fig. 1; P < 0.001).
Xa-clot assay results: Patients in the fondaparinux arm had a
signiﬁcantly lower mean 6-h Xa clot time compared with
patients in the enoxaparin arm [64.9 s (SD 17.7 s) vs. 111.8 s
(SD 29.6 s), P < 0.0001]. There was signiﬁcantly less variabil-
ity of the Xa clot time of fondaparinux compared with
enoxaparin (Table 3, Fig. 1; P < 0.001).
Endogenous thrombin potential (ETP) In the fondaparinux
arm, analysis of the AUC at the 6-h sampling time provided a
mean result of 386.7 mA (SD 51.5 mA). In the enoxaparin
arm, the mean result was 206.4 mA (SD 90.6 mA,
P < 0.0001). There was signiﬁcantly less variability of the
ETP AUC of fondaparinux compared with enoxaparin
(Table 3, Fig. 1; P < 0.001).
Results at 24 and 72 h Anti-Xa concentrations, Xa clotting
times, and areas under the curve for thrombin generation at 24
and 72 h are presented in Table 3. The contrast between the
Table 1 Baseline characteristics in the overall OASIS-5 study and in patients participating in the present study according to randomized treatment
allocation
OASIS 5 (n = 20 078) Enoxaparin (n = 42) Fondaparinux (n = 48) P-value
Age in years, mean (SD) 66.6 (10.9) 62.3 (13.2) 64.6 (10.3) 0.35
*Creatinine, mean (SD) 94.2 (29.6) 71.6 (26.8) 69.8 (17.9) 0.70
History of CV disease
MI, n (%) 5164 (25.7) 15 (35.7) 16 (33.3) 0.81
PCI, n (%) 2332 (11.6) 13 (31.0) 15 (31.3) 0.98
CABG, n (%) 1643 (8.2) 11 (26.2) 10 (20.8) 0.55
Any CAD, n (%) 6856 (34.1) 11 (26.2) 9 (18.8) 0.40
FH CAD, n (%) 4016 (20.0) 9 (21.4) 18 (37.5) 0.10
Stroke, n (%) 1244 (6.2) 1 (2.4) 0 –
PAD 1573 (7.8) 5 (11.9) 3 (6.3) 0.35
CV risk factors
Hypertension, n (%) 13498 (67.2) 25 (59.5) 37 (77.1) 0.07
Diabetes, n (%) 5078 (20.3) 15 (35.7) 15 (31.3) 0.65
History of cancer, n (%) 1184 (5.9) 5 (11.9) 10 (20.8) 0.26
CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; FH CAD, family history of coronary artery disease; MI,
myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous intervention.
*Creatinine units are lmol L)1.
Table 2 Pre- and postrandomization antithrombotic drug use
Overall (n = 20078)
Enoxaparin
(n = 42)
Fondaparinux
(n = 48) P-value
Aspirin pre, n (%) 39 (92.9) 42 (87.5) 0.40
Aspirin post, n (%) 40 (95.2) 48 (100) 0.13
Clopidogrel pre, n (%) 15 (35.7) 18 (37.5) 0.86
Clopidogrel post, n (%) 35 (83.3) 40 (83.3) 1.0
GPIIb/IIIa pre, n (%) 9 (21.4) 18 (37.5) 0.10
GPIIb/IIIa post, n (%) 22 (52.4) 32 (66.7) 0.17
UFH pre, n (%) 2 (4.8) 4 (8.3) 0.50
UFH post, n (%) 8 (19.0) 17 (35.4) 0.08
LMWH pre, n (%) 24 (57.1) 25 (52.1) 0.63
PCI < 6 h 5 (11.9%) 11 (22.9) 0.11
GP IIb/IIIa, glycoprotein IIb/IIIa inhibitor; UFH, unfractionated
heparin; LMWH, low-molecular-weight heparin.
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two randomized treatment groups at 6 h remained evident at
24 and 72 h, although anti-Xa concentrations and Xa clotting
times were lower, and areas under the curve for thrombin
generation were higher. The latter ﬁnding is expected because
the 6-h samples reﬂect peak drug levels, whereas the 24- and 72-
h levels are more likely to be trough levels.
Correlation between assays
There was a strong positive correlation between the anti-Xa
level and Xa clot time (r = 0.952; P < 0.0001) and a strong
negative correlation between anti-Xa levels and the ETP AUC
(r = )0.846, P < 0.0001) at 6 h after the ﬁrst dose of the
study drug.
Sensitivity analyses
Results at 6 h were consistent irrespective of whether patients
received prerandomization treatment with UFH or LMWH
[fondaparinux vs. enoxaparin: anti-Xa 0.49 IU mL)1 (SD
0.24 IU mL)1) vs. 1.22 IU mL)1 (SD 0.50 IU mL)1); P <
0.0001] or they did not receive any prerandomization antico-
agulant treatment [fondaparinux vs. enoxaparin: anti-Xa
0.55 IU mL)1 (SD 0.22 IU mL)1) vs. 1.19 IU mL)1 (SD
0.39 IU mL)1); P < 0.0001].
Discussion
Our results demonstrate that patients in the OASIS-5 trial
receiving 2.5 mg fondaparinux subcutaneously once daily
compared with enoxaparin 1 mg kg)1 subcutaneously twice
dailyhad approximately 50% of the peak anti-Xa concentra-
tion and Xa clotting time and signiﬁcantly less inhibition of
thrombin generation at 6 h after the ﬁrst dose of the study
drug. This difference remained evident at 24 and 74 h although
absolute anti-Xa concentrations and Xa clotting times were
lower and areas under the curve for thrombin generation were
higher at later time points because the 6-h samples reﬂect peak
levels whereas the 24- and 72-h samples reﬂect trough levels.
Our results indicate that patients randomized to enoxaparin
compared with fondaparinux in the OASIS-5 trial received
more intensive anticoagulation and provide an explanation for
the increased bleeding observed in patients who received
enoxaparin. Greater variability of the anticoagulant effect of
enoxaparin compared with fondaparinuxmight also contribute
to the increased risk of bleeding with enoxaparin because
higher peaks are likely to be associated with more bleeding.
Fondaparinux, a synthetic pentasaccharide, acts by the
selective AT-dependent inhibition of FXa; structurally, the
pentasaccharide analogue is too short to bridge AT to
thrombin (FIIa), and thus has no activity against FIIa.
Enoxaparin, a LMWH produced by chemical depolymeriza-
tion ofUFH, also acts byAT-dependent inhibition of FXa, but
in contrast to fondaparinux, some of the LMWH molecules
have sufﬁcient chain length to bridge AT to thrombin, thereby
causing an anti-IIa effect [13]. The higher intensity of antico-
agulation produced by the anti-Xa and anti-IIa effect of
enoxaparin compared with the anti-Xa effect of fondaparinux
is reﬂected by substantially greater suppression of ETP.
The more predictable anticoagulant effect of fondaparinux
compared with enoxaparin may reﬂect the differing propensi-
ties of fondaparinux and enoxaparin to bind non-speciﬁcally to
plasma proteins [14]. Non-speciﬁc protein binding of UFH
molecules to plasma proteins accounts for its unpredictable
anticoagulant effect. Although, compared with UFH, the
shorter chain lengths of LMWH are associated with reduced
non-speciﬁc binding and a more predictable anticoagulant
response, non-speciﬁc binding of LMWH still occurs, account-
ing for some variability in anticoagulant effect. In contrast,
fondaparinux binds selectively to AT, providing a highly
predictable bioavailability, and our ﬁndings demonstrate that
this is associated with a more predictable anticoagulant effect
than LMWH.
The dose of fondaparinux used in the OASIS-5 trial was
selected on the basis of previous dose-ﬁnding studies [15–17],
which showed an optimal efﬁcacy-safety proﬁle at a relatively
low dose. Similar dose-ﬁnding studies have not been performed
for any of the LMWH preparations currently used in the
management of ACS. An even higher dose of enoxaparin than
is currently used was tested in the phase II Thrombolysis in
Table 3 Anti-Xa levels, Xa clot times, and endogenous thrombin potential 6, 24 and 72 h after initial study drug administration
Enoxaparin (n = 42) Fondaparinux (n = 48)
P-valueMean SD Mean SD
6-h anti-Xa (IU mL)1) 1.2 0.45* 0.5 0.2* < 0.0001
6-h Xa-clot (seconds) 111.8 29.6* 64.9 17.7* < 0.001
6-h ETP AUC (mA) 206.4 90.6* 386.7 51.5* < 0.001
24-h anti-Xa (IU mL)1) 0.8 0.3 0.2 0.2 < 0.0001
24-h Xa-clot (seconds) 79.6 20.3 46.2 10.6 < 0.0001
24-h ETP AUC (mA) 264.4 138.8 422.9 63.1 < 0.0001
72-h anti-Xa (IU mL)1) 0.6 0.4 0.3 0.1 0.002
72-h Xa-clot (seconds) 65.5 27.8 48.1 9.0 0.006
72-h ETP AUC (mA) 310.9 132.2 425.7 45.7 < 0.001
ETP AUC, endogenous thrombin potential area under the curve.
*Test for equality of variances: P < 0.001 for each comparison.
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the (OASIS)-5 trial 247
 2009 International Society on Thrombosis and Haemostasis
Myocardial Infarction (TIMI)-11A Study but the higher
dosing regimen was abandoned because of excessive bleeding
[18].
Preservation of efﬁcacy during treatment with less intensive
anticoagulant therapy with fondaparinux compared with
enoxaparin raises the possibility that lower doses of enoxaparin
might produce less bleeding without compromising antithrom-
botic efﬁcacy. Consistent with this hypothesis, a recent
retrospective case series of 1400 patients with ACS treated
with aspirin and clopidogrel reported that enoxaparin given at
a dose of 0.5 mg kg)1 every 12 h prior to PCI and 0.3–
0.5 mg kg)1 thereafter was safe and efﬁcacious [19]. However,
the efﬁcacy and safety of reduced intensity enoxaparin therapy
compared with presently approved dosing regimens remains
unproven.
Our study has several potential limitations. First, we studied
a small subset of patients enrolled in the OASIS-5 trial and
were unable to include patients who did not have a blood
sample collected at 6 h. However, the baseline characteristics of
patients included in our study were comparable with those of
the overall OASIS-5 study population and the differences that
we observed were very large. It is therefore extremely unlikely
that minor differences in baseline characteristics could explain
our results. Second, our analyses included patients who
underwent PCI prior to the 6-h blood collection. However,
this would not have affected our conclusions because the
OASIS-5 protocol recommended the administration of addi-
tional fondaparinux in patients who underwent PCI within 6 h
of administration of fondaparinux (except in those receiving a
glycoprotein IIb/IIIa inhibitor) but did not recommend any
additional enoxaparin in patients who underwent PCI within
6 h of enoxaparin. A subsequent protocol amendment enabled
investigators to add open label heparin at the time of PCI but a
higher proportion of patients randomized to fondaparinux
compared with enoxaparin received additional UFH. Both of
the aforementioned strategies would reduce the contrast
between the two treatment groups. A further limitation of
our study is that some patients received UFH or LMWH prior
to randomization but a sensitivity analysis conﬁrmed that our
results were consistent irrespective of whether patients received,
or did not receive, prerandomization treatment with UFH or
LMWH. Finally, although our results provide a plausible
explanation for differences in the safety and efﬁcacy of
fondaparinux compared with enoxaparin they do not prove
that lower intensity and more predictable anticoagulant effects
of fondaparinux compared with enoxaparin account for the
ﬁndings of the OASIS-5 trial.
In conclusion, our results suggest that the lower rates of
bleeding and improved efﬁcacy of fondaparinux compared
with enoxaparin in the OASIS-5 trial may be explained by a
less intense and more predictable anticoagulant effect of
fondaparinux. Lower doses of anticoagulant than used in the
past may be sufﬁcient to prevent recurrent ischemic events and
death in patients with ACS who are concurrently treated with
aspirin and clopidogrel. Determining the optimal balance for
anticoagulant intensity, whereby antithrombotic efﬁcacy is
maximized and bleeding is minimized, is important because
both reduced ischemic events and bleeding translate into
improved long-term outcomes.
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Fig. 1. Box and whisker plots showing (A) anti-Xa levels (IU mL)1); (B)
Xa clot times (s); (C) AUC ETP (mA) for enoxaparin and fondaparinux.
The boxes represent the ﬁrst to third quartile and the whiskers represent
the upper and lower extremes of the results. Outliers are represented by
horizontal lines above or below the upper and lower extremes of the
results. The horizontal line in the box represents the median.
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